Literature DB >> 7805750

Lymphocyte-activation gene 3/major histocompatibility complex class II interaction modulates the antigenic response of CD4+ T lymphocytes.

B Huard1, M Tournier, T Hercend, F Triebel, F Faure.   

Abstract

The activation requirements for antigen-dependent proliferation of CD4+ T cells are well documented, while the events leading to the inactivation phase are poorly understood. Here, we tested the hypothesis that the lymphocyte-activation gene 3 (LAG-3), a second major histocompatibility complex (MHC) class II ligand, plays a regulatory role in CD4+ T lymphocyte activation. CD4+ class II-restricted T cell clones were stimulated by their relevant antigen (hemagglutinin peptide or diphteria toxoid) and antigen-presenting cells with or without anti-LAG-3 monoclonal antibody (mAb). Kinetic studies were performed to monitor different activation parameters, including the measurement of thymidine incorporation, expression of activation antigens and cytokine secretion. Results showed that the time course from the initial time points up to the peak time point was not modified in the presence of anti-LAG-3 mAb. However, addition of these antibodies, either as whole IgG or as Fab fragments, led to increased thymidine incorporation values for late time points and, hence, to a shift in the decreasing proliferation curve. We also showed that expression of activation antigens, such as CD25, was higher in the presence of anti-LAG-3 mAb, and that cytokine concentrations, i.e. of interferon-gamma or interleukin-4, were higher in the corresponding culture supernatants. In addition, we tested whether the effects of anti-LAG-3 mAb were limited to antigen-dependent, MHC class II-restricted responses. The proliferative responses of CD4+ T cell clones following stimulation with either interleukin-2, mitogens, a combination of anti-CD2 mAb, immobilized anti-CD3 or anti-T cell receptor mAb were not altered by anti-LAG-3 mAb. The allogeneic proliferative response of a CD8+ T cell clone was also not affected. Overall, the present analysis reveals a modulating effect of anti-LAG-3 mAb, mediated specifically on antigen-dependent, MHC class II-restricted responses of CD4+ T cell lines. These results support the view that LAG-3/MHC class II interaction down-regulates antigen-dependent stimulation of CD4+ T lymphocytes.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7805750     DOI: 10.1002/eji.1830241246

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  73 in total

1.  Tumor-specific MHC-II expression drives a unique pattern of resistance to immunotherapy via LAG-3/FCRL6 engagement.

Authors:  Douglas B Johnson; Mellissa J Nixon; Yu Wang; Daniel Y Wang; Emily Castellanos; Monica V Estrada; Paula I Ericsson-Gonzalez; Candace H Cote; Roberto Salgado; Violeta Sanchez; Phillip T Dean; Susan R Opalenik; Daniel M Schreeder; David L Rimm; Ju Young Kim; Jennifer Bordeaux; Sherene Loi; Leora Horn; Melinda E Sanders; P Brent Ferrell; Yaomin Xu; Jeffrey A Sosman; Randall S Davis; Justin M Balko
Journal:  JCI Insight       Date:  2018-12-20

Review 2.  Blocking immune checkpoints in prostate, kidney, and urothelial cancer: An overview.

Authors:  Angela K B Alme; Beerinder S Karir; Bishoy M Faltas; Charles G Drake
Journal:  Urol Oncol       Date:  2016-02-28       Impact factor: 3.498

3.  LAG-3 (CD223) reduces macrophage and dendritic cell differentiation from monocyte precursors.

Authors:  Sandrine Buisson; Frédéric Triebel
Journal:  Immunology       Date:  2005-03       Impact factor: 7.397

Review 4.  New clinical advances in immunotherapy for the treatment of solid tumours.

Authors:  Valentina A Zavala; Alexis M Kalergis
Journal:  Immunology       Date:  2015-03-30       Impact factor: 7.397

5.  Fibrinogen-like Protein 1 Is a Major Immune Inhibitory Ligand of LAG-3.

Authors:  Jun Wang; Miguel F Sanmamed; Ila Datar; Tina Tianjiao Su; Lan Ji; Jingwei Sun; Ling Chen; Yusheng Chen; Gefeng Zhu; Weiwei Yin; Linghua Zheng; Ting Zhou; Ti Badri; Sheng Yao; Shu Zhu; Agedi Boto; Mario Sznol; Ignacio Melero; Dario A A Vignali; Kurt Schalper; Lieping Chen
Journal:  Cell       Date:  2018-12-20       Impact factor: 41.582

Review 6.  Type 1 diabetes pathogenesis and the role of inhibitory receptors in islet tolerance.

Authors:  Tijana Martinov; Brian T Fife
Journal:  Ann N Y Acad Sci       Date:  2019-04-26       Impact factor: 5.691

Review 7.  T-cell Dysfunction in Glioblastoma: Applying a New Framework.

Authors:  Karolina I Woroniecka; Kristen E Rhodin; Pakawat Chongsathidkiet; Kristin A Keith; Peter E Fecci
Journal:  Clin Cancer Res       Date:  2018-03-28       Impact factor: 12.531

8.  Molecular, clinicopathological, and immune correlates of LAG3 promoter DNA methylation in melanoma.

Authors:  Anne Fröhlich; Judith Sirokay; Simon Fietz; Timo J Vogt; Jörn Dietrich; Romina Zarbl; Mike Florin; Pia Kuster; Gonzalo Saavedra; Susana Ramírez Valladolid; Friederike Hoffmann; Lukas Flatz; Sandra S Ring; Carsten Golletz; Torsten Pietsch; Sebastian Strieth; Peter Brossart; Gerrit H Gielen; Glen Kristiansen; Friedrich Bootz; Jennifer Landsberg; Dimo Dietrich
Journal:  EBioMedicine       Date:  2020-08-30       Impact factor: 8.143

Review 9.  Costimulatory and Coinhibitory Receptor Pathways in Infectious Disease.

Authors:  John Attanasio; E John Wherry
Journal:  Immunity       Date:  2016-05-17       Impact factor: 31.745

10.  Role of 4-1BB receptor in the control played by CD8(+) T cells on IFN-gamma production by Mycobacterium tuberculosis antigen-specific CD4(+) T Cells.

Authors:  Carla Palma; Silvia Vendetti; Antonio Cassone
Journal:  PLoS One       Date:  2010-06-08       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.